NLS Pharmaceutics (NCEL) EBITDA (2018 - 2025)
NLS Pharmaceutics (NCEL) EBITDA from Dec 31, 2018 to Dec 31, 2025. The TTM NLS Pharmaceutics (NCEL) EBITDA is -$2.51M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
NLS Pharmaceutics (NCEL) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year | +52.12% |
| 3 Years | -45.46% |
| 5 Years | -1.95% |
| All Time | -9.76% |
Annual EBITDA change of NLS Pharmaceutics (NCEL)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$2.51M | +52.12% |
| 2024 | -$1.65M | -30.96% |
| 2023 | -$2.39M | -84.55% |
| 2022 | -$15M | +30.55% |
| 2021 | -$12M | +327.80% |
| 2020 | -$2.77M | -49.17% |
| 2019 | -$5.45M | +5.83% |
| 2018 | -$5.15M | N/A |
Comparison NLS Pharmaceutics (NCEL) five years EBITDA CAGR with competitors
NLS Pharmaceutics (NCEL) five years EBITDA CAGR is -2.01%.